NCT04731259View on ClinicalTrials.gov

Study to Evaluate the Safety of ATR-04

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Epidermal Growth FactorPapulopustular Rosacea
Interventions
DRUG

ATR-04

ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.

OTHER

Placebo

Placebo

Sponsors

Lead Sponsor

Azitra Inc.
All Listed Sponsors
lead

Azitra Inc.

INDUSTRY

NCT04731259 - Study to Evaluate the Safety of ATR-04 | Biotech Hunter | Biotech Hunter